Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis

Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene. Among the adverse events of elexacaftor, tezacaftor and ivacaftor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li Pomi, Federica, Di Bartolomeo, Luca, Vaccaro, Mario, Lentini, Maria, Cristadoro, Simona, Lucanto, Maria Cristina, Lombardo, Mariangela, Costa, Stefano, Borgia, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503821/
https://www.ncbi.nlm.nih.gov/pubmed/36143881
http://dx.doi.org/10.3390/medicina58091204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503821/
https://www.ncbi.nlm.nih.gov/pubmed/36143881
http://dx.doi.org/10.3390/medicina58091204

Ejemplares similares